Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

An antibody-drug conjugate clears residual cancer cells in blood cancer patients, potentially improving chances of successful transplant eligibility.

Inotuzumab ozogamicin (CD22-targeted ADC) achieves meaningful MRD clearance in adult ALL patients with persistent MRD, offering a novel MRD-directed therapeutic strategy in this high-risk setting where sustained MRD negativity is critical for transplant eligibility.

What the study was

Study design

clinical_trial

Category

hematologic_malignancies

Maturity

clinical

Journal

Blood Cancer Journal

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.